Riemser Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報

◆英語タイトル:Riemser Pharma GmbH - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA904C10815
◆発行会社(調査会社):GlobalData
◆発行日:2018年11月
◆ページ数:26
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:ドイツ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD250 ⇒換算¥27,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥54,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥81,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
Riemser Pharma GmbH (Riemser), formerly Riemser Arzneimittel AG is a distributor of lifecycle management products. The company offers analgesics products, cardiovascular products, over-the-counter medicines, prescription drugs and dental products. It provides medical products for the treatment of infectious diseases, obesity, rheumatology, tuberculosis therapy, neurology, oncology and dermatological disorders such as psoriasis, acromycosis, acne, and herpes. Riemser also offers nutritional supplements. The company has research and development alliances with research institutes, universities, colleges and hospitals across Europe. It has operations in Germany, France and the UK. Riemser is headquartered in Greifswald, Germany.

Riemser Pharma GmbH – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Riemser Pharma Acquires European Rights to Prialt from Eisai 12
Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13
RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14
Private Equity 15
Ardian May Sell Riemser Pharma for USD494.3 Million 15
AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17
Asset Transactions 19
Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19
Acquisition 20
Riemser Pharma to Acquire Intrapharm Labs 20
Riemser Pharma Acquires Keocyt 21
Riemser Arzneimittel To Acquire 49% Stake In anwerina 22
Riemser Pharma GmbH – Key Competitors 23
Riemser Pharma GmbH – Key Employees 24
Riemser Pharma GmbH – Locations And Subsidiaries 25
Head Office 25
Other Locations & Subsidiaries 25
Appendix 26
Methodology 26
About GlobalData 26
Contact Us 26
Disclaimer 26

List of Tables
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Key Facts 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Riemser Pharma GmbH, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 6
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Riemser Pharma GmbH, Deals By Therapy Area, 2012 to YTD 2018 8
Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Riemser Pharma Acquires European Rights to Prialt from Eisai 12
Riemser Pharma Acquires CNS Portfolio from Dolorgiet 13
RIEMSER Arzneimittel Acquires Worldwide Rights Of Ostac From Roche 14
Ardian May Sell Riemser Pharma for USD494.3 Million 15
AXA Private Equity Completes Acquisition Of Riemser Arzneimittel 17
Dermapharm Acquires Hyperthermic Medical Devices Business Unit from Riemser Pharma 19
Riemser Pharma to Acquire Intrapharm Labs 20
Riemser Pharma Acquires Keocyt 21
Riemser Arzneimittel To Acquire 49% Stake In anwerina 22
Riemser Pharma GmbH, Key Competitors 23
Riemser Pharma GmbH, Key Employees 24
Riemser Pharma GmbH, Other Locations 25
Riemser Pharma GmbH, Subsidiaries 25

List of Figures
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 5
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 6
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 7
Riemser Pharma GmbH, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 8
Riemser Pharma GmbH, Medical Devices Deals, 2012 to YTD 2018 10

★海外企業調査レポート[Riemser Pharma GmbH:製薬・医療:M&Aディール及び事業提携情報]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Mikah Pharma, LLC:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Mikah Pharma, LLC Mergers and A …
  • PFSweb, Inc. (PFSW):企業財務及び戦略的SWOT分析
    Summary PFSweb, Inc. (PFSweb), a subsidiary of transcosmos Inc. is an eCommerce service provider company that offers agency services, marketing services, technology services, and financial services. The company offers solutions for omni-channel operations, technology ecosystem, and strategic commerc …
  • Digital China Holdings Limited (861):企業の財務及び戦略的SWOT分析
    Summary Digital China Holdings Limited (DCHL) is an information technology service provider that offers IT distribution and system integration services. The company offers services such as hardware support service, software support service, optional service, basic service package, attendance service …
  • Quintegra Solutions Limited (QUINTEGRA):企業の財務及び戦略的SWOT分析
    Summary Quintegra Solutions Limited (QSL) is a software development company that provides offshore outsourcing and software services. The company's services include application management, product engineering, SAP, testing and validation, and Technology Consulting. It provides application management …
  • Encana Corporation:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Encana Corporation Mergers and …
  • Gaz de France:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Gaz de France Mergers and Acqui …
  • Noevir Holdings Co., Ltd. (4928):企業の財務及び戦略的SWOT分析
    Summary Noevir Holdings Co., Ltd. (Noevir), a subsidiary of Noevir Co. Ltd is a health and beauty product company that develops, produces and sells cosmetics, pharmaceuticals, health food and other products. The company offers cosmetics such as skincare products and hypoallergenic cosmetics. Noevir …
  • Vitol Group:企業の戦略・SWOT・財務分析
    Vitol Group - Strategy, SWOT and Corporate Finance Report Summary Vitol Group - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate act …
  • Ayen Enerji A.S. (AYEN):企業の財務及び戦略的SWOT分析
    Summary Ayen Enerji A.S. (Ayen Enerji) is a power generation company that provides electricity generation, distribution and trading. The company provides power plant development and investment projects. Its investment projects include albania fan river basin HPP investments and akbuk II wind power i …
  • CLC bio AS:企業の戦略的SWOT分析
    CLC bio AS - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and services. T …
  • Ideaya Biosciences Inc:製薬・医療:M&Aディール及び事業提携情報
    Summary Ideaya Biosciences Inc (Ideaya Biosciences) is a biotechnology company that focuses to discover and develop personalized synthetic lethality medicines and immuno-oncology therapies. The company offers medicines targeting the DNA damage and repair; and immuno-oncology therapies targeting the …
  • Ichor Medical Systems Inc-製薬・医療分野:企業M&A・提携分析
    Summary Ichor Medical Systems Inc (Ichor) is a medical equipment company that commercializes electroporation technology for the delivery of vaccines and DNA drugs. The company electroporation technology is used for the treatment and prevention of debilitating diseases. Its trigrid provides DNA drugs …
  • GENERA Biosystems Limited:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' GENERA Biosystems Limited Merge …
  • Fujian Longking Co., Ltd (600388):企業財務及び戦略的SWOT分析
    Summary Fujian Longking Co., Ltd (Longking) is an electrical equipment company that develops, manufactures and markets precipitator products. The company offers precipitator products, flue gas desulfurization system, bulk conveying system and flue gas denitration system. Its products include FE prec …
  • Ningxia Zhongyin Cashmere Co., Ltd.の企業概要及び財務/SWOT分析
    Ningxia Zhongyin Cashmere Co., Ltd. Fundamental Company Report provides a complete overview of the company’s affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual …
  • Direct Flow Medical Inc – Product Pipeline Analysis, 2016 Update
    Summary Direct Flow Medical Inc (Direct Flow) is a medical device company that develops novel transcatheter heart valve technologies. The company provides transcatheter aortic valve implantation device without contrast. It also provides direct flow medical system, a technology for controlled and rel …
  • Bankers Petroleum Ltd:企業の戦略的SWOT分析
    Bankers Petroleum Ltd - Strategic SWOT Analysis Review provides a comprehensive insight into the company’s history, corporate strategy, business structure and operations. The report contains a detailed SWOT analysis, information on the company’s key employees, key competitors and major products and …
  • Otsuka Pharmaceutical Co., Ltd.:(医療機器分野)企業M&A及び提携動向
    Summary Otsuka Pharmaceutical Co., Ltd. (OPC) is a pharmaceutical company. The company develops, manufactures and distributes pharmaceuticals and consumer products for the healthcare industry. Its products include pocari sweat, pocari sweat ion water, oronamin c, calorie mate, nature made, jerubure, …
  • Public Joint-Stock Company Commercial Bank PrivatBank:企業概要・SWOT分析
    This report is a crucial resource for industry executives and anyone looking to access key information about "Public Joint-Stock Company Commercial Bank PrivatBank" The report utilizes a wide range of primary and secondary sources, which are analyzed and presented in a consistent and easily accessib …
  • Domainex, Ltd.:企業M&A・提携・投資動向
    SummaryMarketLine's Company Mergers and Acquisitions (M&A), Partnerships and Alliances and Investments reports offer a comprehensive breakdown of the organic and inorganic growth activity undertaken by an organization to sustain its competitive advantage. MarketLines' Domainex, Ltd. Mergers and Acqu …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆